China Biotech R&D Talent Salary Report 2026: Who Stays and Who Leaves After the Winter

Executive Summary

China’s biotech sector has entered a phase of deepened divergence and structural reshaping following the 2022-2024 funding winter. The polarized recovery has created two distinct talent markets operating under different rules.

Top-tier biotechs — BeiGene, Innovent, Akeso, Legend Biotech — continue to expand R&D investment, backed by commercial-stage product revenue and global clinical pipelines. Their median R&D compensation has breached the ¥1 million mark. Meanwhile, a large number of biotechs with undifferentiated pipelines still struggle with financing, offering ¥600-700K for equivalent roles. The gap has widened from 1.3x to 1.6x in just three years.

This report covers 7 core R&D role categories across 4 seniority levels, with geographic analysis of five major biotech hubs. Benchmarking data draws from BeiGene, Innovent Biologics, Junshi Biosciences, Akeso, Legend Biotech, Zai Lab, and CXO leaders WuXi AppTec, Pharmaron, and Tigermed, supplemented by Sun Tzu Recruit’s direct client engagement data from 2025-2026.

Three core findings:

1. **ADC and CGT talent premiums remain at elevated levels.** Experienced R&D professionals in these therapeutic modalities command 40-60% premiums over equivalent small-molecule roles. The supply-demand ratio sits below 0.5 — meaning two open positions for every available candidate. This is not a short-term spike; the talent pipeline takes 5-8 years to develop, and the industry’s pipeline shift toward these modalities shows no sign of reversing.

2. **Mid-level (3-8 years experience) talent has become the most expensive cohort by growth rate.** Average jump premiums hit 25-30% in 2025-2026, with ADC process development and clinical medical roles reaching 35-40%. This is a direct consequence of the 2022-2024 contraction years, during which a significant portion of this experience cohort either moved to CXOs or left the industry entirely. Now that hiring is recovering, the talent “bathtub” — the missing cohort — is driving price discovery.

3. **AI-driven drug discovery (AIDD) is the fastest-growing role category.** Starting salaries have reached ¥800K with no ceiling in sight. The total addressable talent pool in China is estimated at fewer than 500 professionals who genuinely bridge computational science and drug development experience. Every top-20 biotech and most large pharma companies in China now have dedicated AIDD teams, most of which are actively understaffed.

Industry Talent Landscape

From “Burn Cash, Hire Fast” to “Precision Hiring”

Before 2022, China’s biotech sector operated in a funding-driven growth model. Raise a Series B, and the first order of business was to triple the R&D headcount. A freshly minted PhD specializing in tumor immunology could command ¥600K with no negotiation. The 2022-2024 funding winter changed all of that.

By 2025-2026, three structural shifts define the talent landscape:

First, R&D headcount growth has decelerated sharply. BeiGene’s R&D team stood at approximately 4,200 by end of 2025, growing only 8% year-over-year — a far cry from the 50%-plus growth rates of 2021. Mid-tier biotechs have seen R&D teams shrink in absolute terms, with some going from 300-400 scientists down to 150-200 as they pivoted to leaner operations.

Second, mid-to-senior talent has paradoxically become more expensive even as junior hiring slowed. Entry-level salary growth has moderated to 5-10% annually. But professionals with 3-8 years of experience have become the scarcest resource in the market. The logic is straightforward: during the contraction years (2022-2024), a meaningful number of scientists at this career stage left biotech for CXO roles, crossed over to AI or consumer tech, or exited China’s life sciences sector entirely. Now that the market is recovering, this “missing cohort” has created a structural shortage that simple salary increases cannot quickly resolve.

Third, pipeline differentiation now dictates compensation strategy. Companies with ADC or CGT pipelines are willing to pay significant premiums because their products have clear differentiation advantages. A biotech developing a Claudin 18.2 ADC may pay its Chief Scientific Officer ¥4M+ with options, while a comparable-stage small-molecule focused company may cap the same role at ¥2.5M. The PD-1/PD-L1 “red ocean” is seeing the slowest salary growth as companies prioritize cost control over talent competition.

The CXO Layoff Dividend

The 2024-2025 layoff wave across China’s CXO sector — WuXi AppTec and its subsidiaries (WuXi Biologics, WuXi XDC) cumulatively reduced approximately 5,000 positions, with Pharmaron, Medicilon, and others also contracting — has paradoxically become a talent dividend for biotechs.

In 2025, Sun Tzu Recruit observed a 35% year-over-year increase in CXO-to-biotech placements across CMC, regulatory affairs, and clinical operations roles. The median salary bump for these moves was 25-30%. A concrete example: a Senior Scientist (5 years) at WuXi AppTec hired as CMC Director at a mid-stage biotech saw total compensation move from ¥500-600K to ¥750-900K.

However, not all CXO talent transitions seamlessly. The CXO model is built around serving multiple clients with rapid project switching, while biotech demands deep, sustained focus on a single pipeline. This creates a subtle but important mismatch that hiring managers are increasingly aware of. As a result, a new screening criterion has emerged: biotechs now prefer candidates with “at least 2 years of in-house experience” in addition to CXO background. The handful of professionals who successfully bridge both worlds command a distinct premium over those with only CXO experience.

The AIDD Wildcard

AI-driven drug discovery deserves its own subsection. In 2023, dedicated AIDD teams at Chinese biotechs and pharma companies were rare. By 2025, almost every top-20 biotech and virtually all large pharma companies in China have established AIDD groups. The problem: there are perhaps 500 people in China who genuinely combine computational expertise with drug development experience.

This shortage has created a seller’s market. A Senior Scientist in AIDD with 3-5 years of experience can command ¥1.0-1.3M total compensation. The premium relative to a traditional computational chemist at the same level is 40-50%. And unlike other roles where options can substitute for cash, AIDD candidates are overwhelmingly choosing cash-heavy packages — they know they are in demand and are optimizing for liquidity.The talent sourcing challenge for AIDD is distinct from other roles. The traditional biotech recruitment channels (industry conferences, academic networks, CXO referrals) do not work well because the candidate pool sits at the intersection of two worlds: computational biology (often from AI/tech backgrounds, not pharma) and drug discovery (from pharma, not tech). Finding candidates requires parallel searches in both ecosystems, which most HR teams are not structured to do.

Salary Benchmarks by Role Category

All figures are industry trend estimates covering Shanghai, Beijing, and Suzhou. Total compensation includes base salary, annual bonus, and option valuation (at last round or public market price).

What the data reveals:

CGT and ADC/large molecule categories are growing 2-3x faster than small molecule equivalents. This is not coincidence — China’s pipeline composition is undergoing a fundamental shift. In 2025, ADC candidates accounted for over 30% of all IND submissions, and CGT approximately 15%. Three years ago, those numbers were 18% and 8% respectively.

The supply-demand arithmetic is unforgiving. ADC formulation engineers require at least 5 years of hands-on experience to be truly productive. CGT viral vector specialists require even longer. The education pipeline — PhD programs, postdoc positions — operates on a 4-6 year cycle. Short-term training programs cannot close this gap. As one biotech CEO put it during a recent talent review conversation with Sun Tzu Recruit: “We can’t manufacture experienced ADC scientists. We can only steal them from each other.”

AIDD’s 25% annual growth rate deserves special attention. This number may actually understate the underlying pressure, because the base is still small. As more companies establish AIDD teams and more discovery programs adopt AI-first methodologies, the competition for the tiny pool of qualified candidates will intensify further. The most vulnerable companies are those entering the AIDD space now — they compete not only against other biotechs but against large pharma and tech companies that can offer more stable compensation and better computational infrastructure.

Salary Benchmarks by Seniority

Two critical observations on the seniority curve:

Mid-level is the hottest segment, and the reasons are structural, not cyclical. The 3-8 year cohort represents the “lost generation” of the funding winter. During 2022-2024, many scientists at this career stage faced a painful choice: stay in a contracting biotech sector with limited promotion opportunities, or move to a CXO where headcount was more stable. A significant number chose the latter. Those who stayed often took salary cuts or flat compensation. Now that biotech hiring is recovering, this cohort is being aggressively courted.

Sun Tzu Recruit recently managed a search for an ADC Process Development Director role — a classic 5-8 year experience requirement. We extended offers to five candidates. The first four declined, each holding multiple competing offers. The fifth accepted. This is not an isolated case; it reflects a structural reality where the supply of qualified mid-level ADC and CMC professionals has not kept pace with demand since the market turned.

The second observation concerns the junior tier. Entry-level PhD hiring has slowed noticeably, and starting salaries have largely plateaued at ¥350-450K for traditional small-molecule roles. However, there is a bifurcation within the junior market: PhDs specializing in ADC, CGT, or AIDD-related fields can still command ¥450-550K starting packages, reflecting the pipeline-driven nature of current demand.

Lead-level (VP/CSO) compensation shows the widest dispersion, from ¥1.8M to ¥4.0M+. The premium factors are well understood: MNC global leadership experience (30-50% premium), company tier (top-tier biotech vs. mid-tier), and pipeline modality (ADC/CGT over small molecule). What is less discussed is the increasing role of options in total compensation at this level — options now account for 40% of total package at the median, meaning that the actual value realized depends heavily on the company’s execution capability and market conditions at exit.

City-by-City Comparison

Suzhou’s growth trajectory is the story to watch. Suzhou BioBay has evolved into one of China’s densest biotech clusters, anchored by Innovent Biologics, BeiGene’s Suzhou R&D center, Zai Lab, and dozens of ADC-focused startups. The 16% year-over-year salary growth has outpaced Shanghai, and the gap is expected to narrow further.

A subtle but important dynamic is at play: the “Shanghai spillover effect.” Some candidates who have spent 5-8 years in Shanghai — facing housing costs that now exceed ¥8-10M for a family-sized apartment near a biotech park — are willing to take a 10-15% pay cut to relocate to Suzhou, where housing costs are roughly half. However, this arbitrage window is closing as Suzhou-based companies raise compensation to retain talent locally. The net effect is a compression of the Shanghai-Suzhou salary differential, from approximately 20% in 2023 to an estimated 13% in 2026.

Beijing’s slower 11% growth reflects a different ecosystem structure. The city’s biotech sector is more heavily weighted toward academic spinouts and early-stage research, with a larger proportion of publicly funded research institutes. While this creates a deep talent pipeline at the junior level, commercial-stage biotechs with the budget to drive salary inflation are less concentrated than in Shanghai or Suzhou.

Guangzhou/Shenzhen remains the laggard by absolute compensation but shows signs of acceleration. The Shenzhen Bay Science City and光明 (Guangming) Science Park investments are beginning to attract anchor tenants and specialized talent. The base is lower — approximately 20% below Shanghai — but the growth trajectory suggests this gap will narrow over the next 2-3 years as more clinical-stage biotechs establish operations in the Greater Bay Area.

Talent Flow Trends

MNC Talent Returning to Domestic Biotechs

This is the most significant talent migration pattern of 2025-2026. Medical directors, clinical development heads, and regulatory affairs leaders with 5+ years at multinational pharmaceutical companies have become the single most sought-after candidate demographic for Chinese biotechs.

The logic is clear: leading Chinese biotechs are evolving from “China innovation” to “global innovation.” BeiGene’s Brukinsa is approved in 70+ countries. Legend Biotech’s Carvykti is a global product. Akeso and Innovent have products in global registrational trials or licensed to MNC partners. To execute global clinical development strategies, these companies need leaders with exactly the experience that MNCs cultivate — global regulatory submission expertise, multi-regional clinical trial design, and relationships with global KOLs.

The compensation math works in candidates’ favor. A China Medical Director at a top MNC typically earns ¥1.2-1.8M total compensation. The same individual moving to a domestic biotech as Global Clinical VP can expect ¥2.5-3.5M with meaningful option packages. The title upgrade — from China-region role to global leadership — is often as motivating as the financial upside.

Sun Tzu Recruit completed a representative search in Q1 2026: a China Clinical Development Head (¥1.5M at a top-5 MNC) was recruited as Global Clinical VP at a Nasdaq-listed Chinese biotech, with total package valued at approximately ¥2.8M including options. The search took four months and required approaching 12 qualified candidates before finding one who was willing to make the move.

Some MNCs are responding with retention mechanisms. “Golden handcuffs” — extended non-compete periods, retention bonuses, and accelerated equity vesting — are being deployed for key China R&D leaders. One MNC we work with extended its China senior leadership departure notice period from 6 to 12 months in early 2026. Whether these measures will be sufficient remains to be seen. The pull from domestic biotechs is not just financial; it is also about scope and autonomy — the opportunity to shape global drug development strategy rather than execute a regional subset of a global plan.

CXO Talent Migration to In-House Roles

The CXO-to-biotech talent flow deserves granular analysis because it is not as straightforward as it appears.

The supply side is clear. The 2024-2025 layoff wave at WuXi AppTec, Pharmaron, and Medicilon released a significant volume of experienced CMC, analytical development, and regulatory talent into the market. Many of these professionals had 5-10 years of experience serving multiple biotech and pharma clients — precisely the kind of broad exposure that biotechs find attractive.

The demand side is more nuanced. Biotechs are eager to hire CXO talent for CMC Director, Head of Regulatory Affairs, and Head of Quality roles. The median salary bump of 25-30% makes the move financially attractive. But there is a growing recognition that CXO experience alone is not sufficient.

The core issue: CXO professionals are trained to service multiple clients simultaneously, with project teams that rotate every 6-18 months. Biotech requires deep, sustained ownership of a single pipeline over a 5-10 year development cycle. A CMC leader who has never managed a single product from IND to BLA may struggle with the sustained pressure and cross-functional coordination that biotech demands.

This has created a preference cascade. Biotechs now explicitly ask for “at least 2 years of in-house experience” when evaluating CXO candidates for senior roles. The small subset of professionals who have worked both at CXOs and at biotechs command a significant premium — often 15-20% above peers with only CXO background.

The practical implication for biotech HR: when evaluating CXO candidates, prioritize those who have managed end-to-end projects for a specific client (not just rotating across clients), and design onboarding programs that explicitly address the transition from service-provider mindset to owner-operator mindset.

CGT Talent: A Tale of Two Markets

The cell and gene therapy talent market in China is not a single market — it is two distinct markets operating at different dynamics.

CAR-T talent has developed into a modest but functioning talent pool of approximately 3,000-4,000 professionals, built by Legend Biotech, Juventas Cell Therapy, Gracell Biotechnologies, and others. While still supply-constrained, this market functions with reasonable efficiency. A Senior Scientist in CAR-T with 5 years of experience can expect ¥800K-1.0M total compensation.

Gene editing and AAV vector talent is a different story. The total addressable pool of professionals with hands-on experience in AAV serotype design, gene editing tool development, and in vivo delivery is estimated at fewer than 500 nationwide. The training pipeline — typically requiring a PhD + 3-5 years of specialized postdoc work — is slow and constrained by the limited number of academic labs in China that focus on these technologies.

The compensation differential is stark: an experienced AAV gene-editing specialist (5 years) commands ¥1.3-1.5M total compensation, approximately 50-60% above a comparable CAR-T scientist. Companies are more willing to offer generous option packages for these roles, recognizing that the talent they hire today will define their competitive position in gene therapy for the next decade.

One emerging trend worth monitoring: several Chinese gene therapy companies have established “satellite labs” in the United States and Europe, hiring local talent while building capabilities that will eventually transfer back to China. This “global talent bridge” strategy is a pragmatic response to the domestic talent shortage but creates its own challenges around team integration and knowledge transfer.

Practical Implications for HR

If You Are a Biotech HR Leader

1. Treat ADC and CGT recruiting as strategic campaigns, not routine hiring.

These are not roles you can fill through standard job postings or LinkedIn searches. The candidate pools are too small, and the qualified candidates are not actively looking — they are being continuously approached by competitors and headhunters. Three tactical recommendations:

• Expand your sourcing radius. ADC process development talent may need to be sourced from large pharma manufacturing sites, not just biotech competitors. CGT talent may need to be sourced from academic labs or overseas returnees.

• Reset your timeline expectations. A typical search for an ADC Process Development Director takes 4-6 months, not 2-3. Plan your pipeline milestones accordingly.

• Prepare for multiple rejections. As the case study above illustrates, even after identifying qualified candidates, you may need to make 4-5 offers before one is accepted. Factor this into your hiring budget and timeline.

2. Make your option packages credible.

The 2022-2024 funding winter has fundamentally changed how candidates evaluate equity compensation. The days of accepting options at face value are over. Candidates now ask three questions:

• What is the company’s cash runway?

• When was the last round, and at what valuation?

• Does the company have a clear path to liquidity (IPO, M&A)?

HR teams need to be prepared to answer these questions transparently. Companies with strong cash positions and clear commercialization milestones will have a significant advantage in option-based negotiations. Companies that cannot answer these questions convincingly should expect candidates to demand higher cash components.

3. When evaluating CXO background candidates, assess “owner-operator mindset.”

Design interview questions that test for sustained ownership:

• “Walk me through a CMC challenge you faced on a single product over 12+ months. How did you handle it?”

• “Tell me about a time you had to make a resource allocation decision that affected one client more than others.”

• “How do you think about trade-offs between speed and quality when you are responsible for a single product’s timeline?”

If You Are a CXO or MNC HR Leader

1. Your retention window is shrinking.

The time between a biotech approaching your top talent and that talent accepting an offer has compressed from 3-6 months to 1-3 months. Several factors are driving this acceleration: specialized headhunters are building faster pipelines, candidates are increasingly proactive about exploring opportunities, and the narrative around Chinese biotech’s global ambitions is becoming more compelling.

Conduct a retention risk assessment annually in Q1. Focus on professionals with 3-8 years of experience, MNC background, and global project exposure — these are the candidates most likely to be targeted by biotech competitors.

2. Your CMC and regulatory talent are biotech’s primary acquisition targets.

If your organization is a CXO, your top CMC scientists and regulatory affairs professionals are being actively courted. Consider these retention strategies:

• Rotate high-potential talent through biotech-facing projects that give them a sense of ownership and client-side perspective

• Create clear career pathways that match the scope and compensation of biotech roles

• For truly irreplaceable talent, consider retention bonuses or accelerated promotion timelines

3. If you are at an MNC, be realistic about what you can retain.

Not every departure can or should be prevented. The pull of a global VP title at a Chinese biotech — with the autonomy to shape global development strategy — is something even the best retention package may not match. Focus your retention efforts on the 20% of talent whose departure would cause disproportionate disruption, and plan succession pipelines for the rest.

Data Notes

• Data nature: Industry estimates synthesized from Aon/Mercer compensation surveys, Liepin/Maimai platform salary data, public company filings (annual reports,IPO prospectuses), and Sun Tzu Recruit’s anonymized client compensation data from 2025-2026.

• Compensation definition: Total annual package including base salary, annual bonus, and option valuation (at last financing round or public market price where applicable).

• Period: Q1 2025 through Q1 2026.

• Coverage: Beijing, Shanghai, Suzhou, Hangzhou, and Guangzhou/Shenzhen. Benchmark companies include BeiGene, Innovent Biologics, Junshi Biosciences, Akeso, Legend Biotech, Zai Lab, WuXi AppTec, Pharmaron, and Tigermed.

• Disclaimer: Compensation figures are directional estimates. Actual compensation varies significantly by company size, pipeline stage, individual capability, negotiation outcome, and market conditions. This report does not constitute compensation or career decision advice.